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Vascular surgeons are seeing increasing numbers
of older patients who have walking impairment
related to intermittent claudication, a manifestation
of mild to moderate lower extremity arterial occlu-
sive disease. Although lower extremity bypass graft-
ing surgery and angioplasty were traditionally
reserved for patients with limb-threatening ischemia,
patient reports of significant activity limitation and
reduced quality of life have become increasingly
important indications for their use. Overall arterial
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Objective: The purpose of this study was the prospective comparison of functional out-
comes after lower extremity bypass grafting surgery, angioplasty, or medical manage-
ment of intermittent claudication.
Methods: The study was designed as a prospective cohort study to compare functional
outcomes for patients with interventional management to medical management, includ-
ing a matched (younger, with more disability) subgroup, followed for a mean of 19
months. Sixteen Chicago-area vascular surgery clinics participated in the study. The sub-
jects were consecutively enrolled patients with an abnormal ankle-brachial blood pres-
sure index (ABI), without signs of rest pain, ulcer, or gangrene, and without prior lower
extremity revascularization procedures. The main outcome measures were changes in
physical functioning, community walking distance, bodily pain, leg symptoms, and ABI.
Results: Of the 526 study patients, 20% underwent revascularization procedures (60 sur-
gical bypass grafting and 44 angioplasty only). The mean ABI improved significantly for
the patients who underwent bypass grafting surgery (0.20; P < .001) and modestly for
the patients who underwent angioplasty (0.09; P < .05). Patients undergoing bypass
grafting and angioplasty maintained highly significant (P < .001) improvements in mean
physical functioning, (17%, 14%), bodily pain (18%, 13%), and walking distance (28%,
27%) scores and reported greater leg symptom improvement. The results were far supe-
rior for the patients with greater improvement in ABI. The conditions of the 277
unmatched patients who underwent medical management declined on all outcome mea-
sures, and the conditions of the 145 matched patients who underwent medical manage-
ment improved 5% (P < .001) on walking distance score. Eighteen percent of the study
patients failed to complete the full study follow-up period.
Conclusion: Most of the functional improvement achieved by patients who underwent
interventional management appears to be related to improved patency rather than to
selection bias or placebo effects. The functional gains were approximately half those
often reported for patients for hip arthroplasty and similar to patients who undergo
elective coronary angioplasty. (J Vasc Surg 2000;31:93-103.)
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patency and limb salvage outcomes have been docu-
mented at academic centers,1 but there are few pub-
lished data that specifically pertain to functional out-
comes after lower extremity revascularization proce-
dures for disabling claudication.2-4 Given the risk of
significant mortality, morbidity, complications, and
cost, the use of invasive procedures for disabling
intermittent claudication remains controversial.5-7
Lower extremity surgical or endovascular proce-
dures are frequently requested by patients with dis-
abilities who are frustrated with the traditional med-
ical management of leg symptoms. There is agree-
ment that patients with claudication are likely to
benefit from aggressive medical management of
comorbid conditions and smoking cessation,8 partic-
ularly because they are at high risk for coronary and
cerebrovascular disease events.9 The Food and Drug
Administration–approved rheologic agent pentoxi-
fylline is often prescribed for patients with claudica-
tion, and cilostazol, a phosphodiesterase-II inhibitor,
has recently received conditional Food and Drug
Administration approval, but there is no consensus
on whether drug therapy provides clinically mean-
ingful benefits.10 Structured, usually hospital-based
exercise and strength training programs have often
been found to be beneficial (whether in place of or in
conjunction with interventional management).11
However, exercise program evaluations have been
mostly short term (often 6 months or less) and inher-
ently involve selected patients who are physically (and
financially) capable of regular attendance.
The purpose of this prospective, observational
study was the examination of change in 18-month
measures of patient self-reported physical function-
ing, community walking distance, bodily pain, and
leg symptoms, which are the most important end-
points in the evaluation of treatment options for
patients with intermittent claudication. In addition,
a patient’s ankle-brachial index (ABI), a measure of
the ratio of resting ankle systolic blood pressure to
pressures in the brachial arteries, was measured to
characterize the hemodynamic changes and the
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Table I. Sample descriptive statistics at enrollment by patient treatment group
All study Medical Matched medical Bypass grafting  
patients management management surgery Angioplasty
(n = 526) (n = 277) (n = 145) (n = 60) (n = 44)
Sociodemographic characteristics
Mean age (SD) 69 (10) 71 (9) 66 (8) 66 (9) 63* (11)
Male sex 421 (80%) 215 (78%) 124 (86%) 46 (77%) 36 (82%)
African-American race 87 (16%) 61 (22%) 19 (13%) 14 (23%) 5 (11%)
Married 315 (59%) 164 (59%) 88 (61%) 33 (55%) 30 (68%)
Education > high school 401 (76%) 214 (77%) 104 (71%) 45 (75%) 38 (86%)
Work full or part time 109 (21%) 61 (22%) 19 (13%) 13 (22%) 16† (36%)
VA clinic site 270 (51%) 129 (47%) 100 (69%) 26† (43%) 15† (34%)
Academic office site 138 (26%) 78 (28%) 22 (15%) 19† (32%) 19† (43%)
Community office site 118 (22%) 70 (25%) 23 (16%) 15 (25%) 10 (23%)
Health status
Heart disease 246 (47%) 120 (43%) 76 (52%) 30 (50%) 20 (45%)
Diabetes 176 (33%) 87 (31%) 57 (39%) 18 (30%) 14 (32%)
Hypertension 364 (69%) 179 (64%) 111 (77%) 44 (73%) 30 (68%)
ABI < 0.5 135 (25%) 63 (23%) 32 (22%) 33† (55%) 6 (14%)
No/mild comorbidity 183 (35%) 102 (53%) 39 (27%) 20 (33%) 22* (50%)
Moderate comorbidity 163 (31%) 93 (34%) 43 (28%) 19 (32%) 8 (18%)
Severe comorbidity 180 (34%) 82 (30%) 63 (43%) 21 (35%) 14 (32%)
Current smoker 148 (28%) 63 (23%) 49 (34%) 21 (35%) 15 (34%)
Exercised regularly 171 (33%) 114 (41%) 37 (25%) 9 (15%) 11 (25%)
Pentoxifylline 86 (16%) 50 (18%) 22 (15%) 10 (17%) 4 (9%)
Lipid-lowering drugs 151 (29%) 78 (28%) 42 (29%) 16 (27%) 15 (34%)
Leg symptoms
Duration of leg symptoms > 2 years 302 (57%) 163 (59%) 83 (57%) 38 (63%) 18 (41%)
Severe or very severe leg symptoms 220 (42%) 52 (19%) 93 (64%) 46 (77%) 29 (66%)
Prior willingness to undergo procedure 254 (48%) 73 (26%) 106 (73%) 44 (73%) 31 (71%)
Died during follow-up period 40 (8%) 25 (9%) 13 (9%) 1 (1%) 1 (2%)
Attrition
Mean follow-up period (months; SD) 19 (4) 18 (4) 19 (4) 20* (4) 21* (4)
Lost to follow-up examination (all causes) 97 (18%) 52 (19%) 34 (23%) 7 (12%) 4* (9%)
VA, Veteran’s Affairs; ABI, ankle-brachial index.
*P < .05, with χ2 test or t test, bypass grafting surgery or angioplasty versus matched medical management.
†P < .001, with χ2 test or t test, bypass grafting surgery or angioplasty versus matched medical management.
severity of vascular disease. Although they are repre-
sentative of only one segment of the large and grow-
ing population of older patients with peripheral vas-
cular disease, most of whom report atypical leg pain
or remain asymptomatic,12 these results should be
broadly generalized to referred patients with mild to
moderate vascular disease who contemplate a more
aggressive specialty treatment of leg pain produced
after walking short distances.
METHODS
Patient sample and study protocol. All the
study patients were enrolled from 1993 to 1995 at
visits to one of the 16 participating Chicago-area
academic (n = 5), community (n = 8), or academi-
cally-affiliated Veteran’s Affairs (VA; n = 3) clinics.
The details about the participating investigators, the
enrollment procedures, and the follow-up examina-
tion protocol have been previously published.13
Institutional Review Board approval was obtained at
all the participating hospitals, and all the patients
signed informed consent forms.
At enrollment, all the patients had an abnormal
ABI14 and were without prior lower extremity revas-
cularization procedures or symptoms of limb-threat-
ening disease, such as rest pain, gangrene, or skin
ulcers. To maximize the willingness to enroll and
maintain contact with this geographically and demo-
graphically diverse patient sample, the follow-up
examination was conducted via three sequential, no-
cost home visits by project home health nurses at 6-
month intervals from enrollment. With portable
Doppler scan equipment, the project nurses con-
ducted in-home lower extremity blood pressure
examinations scheduled to coincide with the comple-
tion of mailed health status questionnaires.15 ABI
measurement was made on the basis of the lowest leg
mean of dorsalis pedis and posterior tibial pressures
indexed to the highest of the two brachial pressures.
Patient age, sex, race, education, marital status,
medication use, smoking and exercise habits were
obtained at enrollment by project coordinators at
each office or clinic site. The comorbid conditions at
enrollment were categorized as having a mild, mod-
erate, or severe impact on functional status on the
basis of the most severe of 15 self-reported chronic
conditions.16 Severity classification (mild, moderate,
severe) of comorbid conditions was empirically
derived from previously published analyses of the
effect of comorbid conditions on physical function-
ing and walking impairment.3,13
Study outcomes. The primary study outcome was
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Table II. Baseline and 18-month follow-up physical functioning, walking distance, bodily pain, and ankle
brachial index change scores and effect size* by patient group
Medical  Matched medical Bypass grafting
management management surgery Angioplasty
(n = 277) (n = 145) (n = 60) (n = 44)
SF36 physical functioning score
Baseline mean (SD) 55 (20) 38 (20) 32 (17) 42 (20)
Follow-up period mean (SD) 53 (22) 40 (20) 49 (26) 56 (20)
Change score mean (SD) –2 (19) 3 (23) 17† (26) 14† (21)
Effect size –0.1 0.12 0.66 0.65
WIQ walking distance score
Baseline mean (SD) 0.45 (0.26) 0.19 (0.17) 0.14 (0.14) 0.20 (0.18)
Follow-up period mean (SD) 0.43 (0.25) 0.24 (0.20) 0.43 (0.32) 0.48 (0.28)
Change score mean (SD) –0.02 (0.21) 0.05† (0.17) 0.28† (0.32) 0.27† (0.28)
Effect size –0.11 0.31 0.90 0.98
SF36 bodily pain score
Baseline mean (SD) 60 (21) 45 (24) 39 (18) 43 (25)
Follow-up period mean (SD) 59 (20) 50 (21) 57 (23) 56 (20)
Change score mean (SD) –1 (19) 5‡ (23) 18† (26) 13† (21)
Effect size –0.04 0.2 0.69 0.6
Lowest leg ABI
Baseline mean (SD) 0.59 (0.15) 0.61 (0.16) 0.49 (0.17) 0.63 (0.14)
Follow-up period mean (SD) 0.58 (0.17) 0.59 (0.19) 0.69 (0.28) 0.72 (0.20)
Change score mean (SD) –0.01 (0.14) –0.02 (0.16) 0.20† (0.25) 0.09‡ (0.18)
Effect size –0.06 –0.12 1.17 0.64
WIQ, Walking Impairment Questionnaire; ABI, ankle-brachial index.
*Effect size = (mean follow-up period – mean baseline)/SD of baseline. 
†P < .05, within group-paired Wilcoxon signed rank sum test or t test.
‡P < .001, within group-paired Wilcoxon signed rank sum test or t test.
All comparisons between matched medical and bypass or angioplasty groups, P < .05.
change in the SF36 Health Status Survey physical
functioning (PF) score, on the basis of patient ratings
of difficulty in vigorous and moderate activities (lifting
or carrying, climbing stairs, bending, kneeling or
stooping, walking three distances, and bathing or
dressing).17 The 10-item scale is scored from 0 (worst,
greatly limited in all 10 items, including walking one
block) to 100 (best, not limited at all for all 10 items,
including walking more than a mile). SF36 PF scores
have been found to be well correlated (r = .68) with 
6-minute walk test results for patients with claudica-
tion who are undergoing medical management.18
Although only 16% of the general US population with
PF scores between 30 and 39 report being able to walk
one block without difficulty, this percentage grows to
50% for people with scores in the 50 to 59 range and
to 79% for people with scores between 60 and 69.17
The secondary treatment outcomes included
change in the claudication-specific Peripheral Arterial
Disease Walking Impairment Questionnaire (WIQ), a
measure of pain-free community walking distance pre-
viously validated with correlations with peak treadmill
walking time.19 The WIQ score reflects a patient’s rat-
ings of four degrees of difficulty in walking up to seven
distances (50 feet to five blocks), scaled from 0 (worst,
cannot walk indoors) to 1.0 (best, no difficulty walk-
ing five blocks). The other outcomes included change
in the SF36 bodily pain score (on the basis of two
Likert scale items rating severity of bodily pain during
the previous 4 weeks) and change in a patient’s lowest
leg ABI. The ABI was initially measured at the partic-
ipating hospital blood flow laboratories, and follow-up
ABI was computed from the most diseased leg at base-
line. Finally, the study patients were asked to rate the
severity of the leg symptoms and how much more
active they would be if they were free of leg symptoms.
Any subsequent hospitalizations were self report-
ed. The relevant medical records were reviewed to
validate the patient reports of endovascular or surgi-
cal procedures. For the patients who underwent
procedures (or other hospitalizations), the home vis-
its were rescheduled for at least 3 months after dis-
charge to avoid early post-hospital recovery periods.
Death information was verified with a search of the
National Center for Health Statistics National Death
Index Plus for 1994 to 1996.
Treatment groups, selection bias, and attrition.
Treatment selection differences inevitably bias obser-
vational comparisons of patient outcomes. In this
study, approximately 65% of the patients who were
managed interventionally as opposed to only 50% of all
the patients who were managed medically indicated
that urging by their “regular, primary care” doctor was
an important reason for making the appointment at
which they were enrolled for the study. Prior research
on study patients who initially underwent surgery or
angioplasty has revealed that ABI, leg symptom sever-
ity, walking distance, and the degree of prior willing-
ness to have a hospital procedure to improve walking
ability all predicted subsequent interventional manage-
ment.20 To estimate the influence of these selection
effects, key treatment selection variables were used to
designate the most comparable subgroup of patients
for medical management. A computer algorithm was
used with empirically derived cutoff values for seven
baseline variables that predicted the highest likelihood
of interventional management (age, prior willingness
to undergo a hospital procedure, baseline SF36 PF and
bodily pain scores, WIQ walking distance score, leg
symptom severity, and ABI).20 This selection algo-
rithm was applied to the medical management group
as a whole to simultaneously identify a younger, but
functionally much more limited, comparative sub-
group of patients for medical management. This com-
parison group provided the most appropriate possible
test of the extent to which differences in outcomes
were related to treatment rather than placebo or
regression to the mean effects.21
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Table III. Results for technically successful versus unsuccessful procedures (n = 104)
ABI change > 0.1 (mean [SD]) ABI change < 0.1 (mean [SD])
Bypass grafting surgery n = 37 n = 23
SF36 physical functioning score 28 (23) –0.8 (18)
WIQ walking distance score 0.43 (0.27) 0.01 (0.23)
SF36 bodily pain score 25 (24) 5 (24)
ABI 0.36 (0.15) –0.01 (0.12)
Angioplasty only n = 22 n = 22
SF36 physical functioning score 20 (23) 7 (17)
WIQ walking distance score 0.35 (0.28) 0.20 (0.26)
SF36 bodily pain score 12 (24) 13 (18)
ABI 0.23 (0.11) –0.01 (0.01)
ABI, Ankle-brachial index; WIQ, walking Impairment Questionnaire. 
With respect to patients who underwent inter-
ventional management, the outcomes for the patients
who underwent angioplasty alone were analyzed sep-
arately from the outcomes of the patients who under-
went surgical bypass grafting procedures. When a
patient underwent both procedures (whether staged
within a single admission or in a subsequent hospi-
talization), the patient was classified as a bypass graft-
ing patient, for the definitive revascularization proce-
dure. This approach created the following four sepa-
rate patient groups: matched medical management,
unmatched medical management, angioplasty only,
and bypass grafting surgery.
To capture the effects of potentially multiple
interventions over time, the study design was based
on time from enrollment, not from a given (first)
procedural intervention. Single baseline and follow-
up measures therefore were computed for all the
study patients, rather than life-table methods, which
are appropriate for the continuous follow-up of a
discrete procedure. For patients who underwent
interventional management, either a single pre-pro-
cedure observation or the mean of multiple pre-pro-
cedure observations was compared with either a sin-
gle follow-up observation or the mean of multiple
follow-up observations. For patients who underwent
medical management, the baseline value was the
enrollment value and the follow-up value was com-
puted as the mean of (up to three) follow-up obser-
vations. With the exclusion of post-hospitalization
recovery periods, any post-intervention follow-up
results recorded at second, third, or fourth visits are
averaged to provide a mean endpoint to compare
with baseline. The follow-up measures thus average
the patient’s ups and downs, giving “credit” for sub-
sequent, secondary procedures that preserve func-
tion, or conversely, reducing overall benefits when
an initially successful procedure failed.
Patency (primary or assisted) was defined as an
overall change in the ABI of more than 0.1. Given
the averaging formula for multiple examinations,
this measure represents a conservative definition of
technical procedural success.8 It was expected that a
substantial number of enrolled patients might die or
become incapacitated. For these patients, the last
observed functional outcomes were analyzed.22
Statistical analysis. The changes between base-
line and follow-up measures within each patient
group were analyzed with paired, two-tailed t tests
for the ABI and SF36 scores and the paired
Wilcoxon signed rank sum test for the WIQ walking
distance score. Effect sizes were calculated as the
mean follow-up period minus the mean baseline
divided by the standard deviation of the baseline to
provide a unit of measure-free estimate of within-
group change.23 Because all the change scores were
normally distributed, two-tailed t tests were used to
test the significance of the differences. The χ2 test
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Table IV. Regression analysis results: baseline and treatment characteristics as predictors of follow-up SF36
physical functioning score (n = 526; R2 = .44)
Coefficient SE P value
SF36 physical functioning score 0.4 0.04 <.0001
WIQ walking distance score 17.2 3.9 <.0001
SF36 bodily pain score 0.1 0.04 .04
ABI 4.8 5.3 .36
Severe or very severe leg symptoms –1.9 1.9 .31
Duration of symptoms > 2 years –2.3 1.6 .14
Age –0.4 0.09 .0001
Male sex 2.6 2.3 .26
African-American race –4.1 2.2 .06
VA clinic enrollment –6.2 2.3 .006
Academic office enrollment 1.3 2.2 .56
> High school education 1.9 1.8 .29
Married –4.0 1.7 .01
Work full or part time –0.2 2.1 .93
Severe comorbidity –5.8 1.9 .002
Moderate comorbidity –2.6 1.9 .18
Exercise regularly 2.9 1.7 .20
Current smoker –2.0 1.8 .26
Angioplasty patient 9.7 3.2 .002
Bypass grafting surgery patient 12.1 3.0 .0001
Matched medical patient 1.5 2.2 .49
Constant 50.6 9.5 <.0001
WIQ, Walking Impairment Questionnaire; ABI, ankle-brachial index; VA, Veteran’s Affairs.
was used to test the differences in the proportion of
patients in each group whose conditions improved
(as opposed to stayed the same or worsened) from
baseline to follow-up examination on individual leg
symptom severity items. Finally, ordinary least
squares multiple regression analysis was used to test
the effect of treatment group status (bypass grafting
surgery, angioplasty, matched and unmatched med-
ical management) in the prediction of follow-up
SF36 PF scores controlling for patients’ baseline PF
score, walking distance, bodily pain, ABI, age, sex,
race, employment, marital status, clinic enrollment
site (VA, community, academic), severity of comor-
bid conditions (three levels), smoking and exercise
habits, leg symptom severity, and duration of claudi-
cation symptoms (greater or less than 2 years).
RESULTS
Interventional procedures. A total of 526
patients completed at least one study follow-up
examination visit. During the mean 19-month peri-
od from enrollment to the last follow-up examina-
tion, a total of 104 study patients (20%) underwent
lower extremity bypass grafting or angioplasty pro-
cedures. Of these 104 patients, 17 underwent both
surgical and endovascular procedures and were
therefore analyzed with the 43 other patients for
surgical bypass grafting (for a total of 60 patients for
bypass grafting). An additional 44 patients under-
went angioplasty procedures only. Of the 61 total
angioplasty procedures, 40 were at the iliac level,
and, of the 21 at the femoral level, only three
extended to the popliteal level. The bypass grafting
procedures included 36 femoropopliteal, 10 aorto-
bifemoral, 10 femorofemoral, two aortobiiliac, one
aortobipopliteal, and one profundaplasty procedure.
The mean time from enrollment to lower extremity
revascularization procedure was 5.4 months, and
two thirds of all the patients underwent procedures
within 6 months of enrollment and more than 80%
within 1 year. The 32 patients who underwent diag-
nostic lower extremity angiography but did not have
angioplasty or bypass grafting surgery are grouped
with other patients for medical management.
Matching criteria and baseline differences in
treatment groups. A total of 145 patients for med-
ical management were identified with the matching
of criteria cutoffs as the patient group that most
closely resembled the patients for interventional
management at enrollment. No statistically signifi-
cant mean differences between the patients who
were matched and interventionally managed existed
for six of the seven matching variables (age, baseline
SF36 PF, bodily pain scores, WIQ walking distance
score, willingness to undergo a procedure, and leg
symptom severity). The patients who underwent
interventional management, notably those who
underwent bypass grafting procedures, had a signif-
icantly lower mean ABI at baseline (0.55 vs 0.60; P
= .005). As compared with the other patients who
underwent medical management and as intended by
the matching criteria, the matched patient group
was younger, rated the leg symptoms as severe (64%
vs 18%), and were much more willing to undergo a
procedure for the legs (73% vs 26%). Although unin-
tended by the matching algorithm, the patients who
were matched and medically managed were more
commonly enrolled at the VA sites (69% to 47%).
More than 40% of the 277 unmatched patients
reported engaging in “regular physical exercise” at
baseline as compared with only 25% of the patients
who were matched and medically managed and the
patients for angioplasty and only 15% of the patients
for bypass grafting surgery.
Table I illustrates the full range of baseline differ-
ences in sociodemographic, medical history, medica-
tion use, leg symptom significance, and study attri-
tion among the four separate treatment groups. As is
consistent with the younger age, the patients for
angioplasty were significantly more likely to be work-
ing full or part time at enrollment (36%) and there
were more patients (50%) who reported mild or no
comorbid conditions. The patients who underwent
bypass grafting surgery and angioplasty were dispro-
portionately enrolled at academic, rather than VA,
sites. The bypass grafting surgery group had a signif-
icantly higher proportion of patients (55%) with the
lowest ABI (<0.05). The prevalence of patient self-
reported hypertension, diabetes, and heart disease (as
indicated by a history of heart failure, angina, previ-
ous myocardial infarction, previous coronary artery
bypass grafting surgery, or angioplasty) was roughly
equivalent in each of the four groups.
Few significant differences in medication use
existed between groups. At enrollment, 16% of the
study patients reported regular use of pentoxifylline
and 28% used lipid-lowering drugs (18% used 3-
hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors). A total of 71% of the study patients were
taking aspirin regularly, and an additional 7% were
taking warfarin sodium. Other widely prescribed
drugs included diuretics (29%), angiotensin-convert-
ing enzyme inhibitors (35%), vasodilators (12%),
nitrates (19%), calcium channel blockers (43%), and
beta blockers (21%). Among the 105 female patients,
21 (20%) reported taking estrogen.
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Attrition and disease progression. A total of
97 study patients (18%) failed to complete the full
study follow-up period. Of these, 40 patients (8%)
died. The death certificate data indicated that 23
deceased patients had died of cardiovascular disease
causes (57%) and that 30% of the remaining deaths
were attributed to cancer and pneumonia. There
were only two deaths among the bypass grafting and
angioplasty groups (unrelated to procedures). A
total of 16 patients (3%) became incapacitated and
were unable to continue study participation, includ-
ing four patients who had disabling strokes and
three patients with disabling cardiac events. Twenty-
five patients (5%) were lost to follow-up examina-
tion, including four patients who were placed in
nursing homes, and 16 additional patients (3%)
refused further participation after one or more fol-
low-up visits. Attrition was heaviest in the medically
managed groups, as compared with the bypass graft-
ing or angioplasty groups (20% vs 11%). Five
patients underwent below-knee amputations (three
after procedures and two while undergoing medical
management), and there were three toe amputa-
tions. It was impossible to determine whether the
below-knee amputations after procedures by 4 and 5
months, respectively, were iatrogenic or related to
underlying disease progression. The mean overall
study follow-up time was greatest for the patients
who underwent interventional management, in part
because of the need to schedule home visits around
periods during and shortly after hospitalization and
in part because of lower study attrition.
Comparisons of baseline and follow-up out-
come measures. Table II provides comparisons of
mean change scores, effect sizes, and results of
paired within-group significance tests. The scores
are displayed as baseline (enrollment or mean of pre-
procedure intervals) and follow-up (mean of all
post-enrollment or post-procedure intervals) for
each continuous outcome measure. Effect size cal-
culations indicate a three-fold to five-fold difference
in the magnitude of change between the matched
medically and interventionally managed groups. The
patients who were unmatched and underwent med-
ical management had non-significant declines on
each of the four outcome measures. The patients
who were matched and underwent medical manage-
ment had small, non-significant improvements in
mean PF and bodily pain scores, a modest but sig-
nificant 5% (P < .001) improvement in mean walk-
ing distance, and little change in mean ABI. In con-
trast, the patients who underwent bypass grafting
and angioplasty had much larger overall improve-
ments (P < .001) in mean SF36 PF (17%, 14%),
bodily pain (18%, 13%), WIQ walking distance
(28%, 27%), and ABI (0.20, 0.09).
Mean outcomes were plotted for each study inter-
val and revealed a similar pattern. Virtually all the
gains for the patients who underwent interventional
management occurred within the first 6-month inter-
val (when two thirds of all procedures occurred) and
were maintained at the same higher level at each sub-
sequent follow-up examination. In comparison, these
line graphs were virtually flat across all three 6-month
study follow-up intervals for the two medically man-
aged groups, indicating no overall mean change from
baseline enrollment for these patients.
These results were consistent with the propor-
tion of each group that reported improvement of at
least one Likert scale level on leg symptom ques-
tionnaire items. The patients for bypass grafting
surgery and angioplasty reported the largest
improvement on leg symptom severity (57%, P <
.05; 34%, NS) and activity limitation (32%, P < .05;
43%, P < .001) items. A nonsignificant but substan-
tial number of matched and unmatched patients
who were medically managed also reported some
improvement from baseline leg symptom severity
(14%, 32%) and activity limitation (13%, 14%).
Patency results for patients for interventional
management. Table III presents the results separately
for the patients who underwent interventional man-
agement who had a change in ABI of more than 0.1.
There was a huge improvement in functional and pain
outcomes for the patients who underwent more suc-
cessful procedures (62% of patients for bypass grafting
and 50% of patients for angioplasty). The 28% PF score
(and 0.36 ABI) improvement for patients who under-
went successful bypass grafting contrasts with no
improvement among the patients with poorer patency
outcomes: the patients who underwent successful
angioplasty had three times the functional improve-
ment as others. It should be noted that change in ABI
may understate overall hemodynamic improvement
for some patients who undergo more proximal (iliac)
revascularization procedures. The correlation between
ABI and PF change for patients who underwent inter-
ventional management was r = 0.45 (P < .001).
Regression results. Table IV presents regression
analysis results that test the effects of bypass grafting
surgery, angioplasty, and matched (as compared with
unmatched) medical management on follow-up PF
score. These results illustrate the overall effects of
the treatment group controlled for the full range of
patients’ baseline functional, medical, and sociode-
mographic characteristics. Regression coefficients
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reflect predicted points of follow-up PF score posi-
tively or negatively associated with each variable.
Bypass grafting surgery was associated with a
12% improvement (P = .0001) and angioplasty with
a 9.7% improvement (P = .002) in follow-up SF36
PF scores as compared with unmatched medical
management. The matched patients were associated
with an insignificant 1.5% difference from the
unmatched patients. The only significant positive
predictors of follow-up SF36 PF were baseline SF36
and WIQ walking distance scores. The significant
predictors of declining function included age (–0.4
points per additional year of age; P = .0001), severe
comorbidity as compared with no or mild comor-
bidity (–5.8 points; P = .002), VA clinic enrollment
as compared with community office enrollment
(–6.2 points; P = .006), and being married at base-
line (–4.0 points; P = .01).
DISCUSSION
This study showed significant improvements in
self-reported physical functioning, walking distance,
bodily pain, ABI, and leg symptoms for patients with
claudication who underwent lower extremity bypass
grafting surgery and angioplasty. The patients who
underwent invasive procedures had significantly bet-
ter functional outcomes than the small improvement
seen in the patients who underwent medical man-
agement who were most severely impaired at base-
line. The gains made by patients for interventional
management generally extended over the full follow-
up period, persisted after controlling for a number of
significant baseline covariates in multiple regression
analyses, and were associated with improvement in
lower extremity blood flow. These gains were con-
centrated among the patients with the most success-
ful technical outcomes.
The largest functional effects in the medical out-
comes literature are associated with total hip or knee
arthoplasty for osteoarthritis. The 1-year mean SF36
PF improvement for these patients typically ranges
between 20 and 30 points.24 The gains in PF score
reported here for patients who underwent interven-
tional management (17.1 for bypass grafting and
13.7 for angioplasty) are slightly lower than the 19-
point change in PF found 6 months after elective
coronary angioplasty.25 However, although the
patients for coronary angioplasty had a pre-proce-
dure mean PF score of 59.0, the patients for inter-
ventional management in this study had a mean
baseline of 36.2. The national PF average for the
general US population aged 65 years and more is
69.4.17 Because the ability to walk is such a critical
predictor of subsequent disability, physical function-
ing improvements at the lower end of the clinical
spectrum may be even more important than similar
improvements at the higher end of the functional
spectrum.26,27
The results of this study support prior findings
on the functional benefits of vascular surgery.28 In
1989, Lundgren et al2 found significant functional
improvements associated with lower extremity
bypass grafting surgery (with and without an exer-
cise program) versus exercise alone for a randomized
sample of 75 patients with claudication in Sweden.
At 1 year, 75% to 90% of patients for surgical treat-
ment had maximum walking distances greater than
600 meters as compared with only 10% to 20% of
the exercise-only group. Currie et al4 reported a 3-
month follow-up period for selected English patients
who underwent lower extremity bypass grafting
surgery (n = 34), angioplasty (n = 74), or exercise-
only therapy (n = 78). The mean improvement in
SF36 PF score for the patients for bypass grafting
surgery in this study was equivalent to the 18-point
gain reported for the English patients for bypass
grafting surgery. The gain associated with angioplas-
ty in this study was somewhat less than the 18-point
3-month gain of the English patients, and the 3-
point gain for the English exercise group was equiv-
alent to the results for the patients for medical man-
agement studied here.
Several important methodologic limits of this
uncontrolled, hypothesis-generating study should
be emphasized. First, as is clearly indicated by the
differing rates of study attrition, there were impor-
tant and unmeasured differences that determined
which enrolled patients subsequently underwent
procedures. The study was designed to capture the
usual and typical care at more than a dozen partici-
pating institutions and includes the results of proce-
dures subsequently performed at other, non-study
hospitals. Whereas the failure rates reported here
reflect poor performance in comparison with pub-
lished academic series, they may unfortunately be
more representative of results across the broad range
of area practice.
Perhaps most importantly, the outcomes are pre-
sented here as differences in group means, the stan-
dard approach to measuring differences between sys-
tems and providers of care in observational research.
This obscures the important predictors of individual
patient outcomes within treatment groups (eg, for
patients whose surgical or endovascular treatment
ultimately failed or for some patients whose condi-
tions improved significantly without hospital proce-
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dures). A validated, risk-adjusted regression model
could provide a valuable prognostic tool for inform-
ing patients about their probabilities of specific func-
tional outcomes. The results presented here are a
first step in providing potentially important informa-
tion for clinicians seeking to advise patients about
the appropriateness and likely benefit of interven-
tional management of disabling claudication, a con-
dition destined to be increasingly common among
the older population of the next century.
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DISCUSSION
Dr John M. Porter (Portland, Ore). I congratulate Dr
McCarthy on his excellent presentation and Dr Feinglass,
the senior author of the manuscript. This is another in a
series of papers from Northwestern, and now from Rush,
attempting to analyze the outcome of claudication treat-
ment in terms of the patient-completed questionnaires
that cover a variety of areas, such as social function, gen-
eral body strength, ability to walk, etc. This is a combina-
tion of outcomes that I refer to as the “feel-good” out-
comes. I am generally concerned about the ability of
patient-administered questionnaires to assess the outcome
of almost anything, especially vascular surgery. All of these
tests have been validated, but one has to make sure that
one understands the meaning of the word validate. It sim-
ply means that someone, somewhere, did some sort of
objective study that purported to correlate to some degree
with the questionnaire. It may not be as impressive as it
sounds.
There are two potential problems with this manu-
script, and the author has addressed these. In the first
place, the ankle-brachial index increase in the surgery
patients was only 0.2 and in the angioplasty patients was
less than 0.1. These increases are virtually within the error
of repeat ankle-brachial index observations and by them-
selves do not inspire confidence. I do believe the subgroup
analysis, however, helps that considerably. The fact that
the patent repair patients had a higher score than the
occluded repair patients is reassuring.
However, we are left with a problem that the patients
who agree to undergo invasive therapy were likely a dif-
ferent group from those who did not. Hence, the haunt-
ing doubts about flawed study design. This could only be
examined in a prospective randomized trial in which some
patients are randomized to invasive treatment and some
are not. This would be very difficult. I would like the
author to comment on this potential for the future.
And this brings me to my final point, which is what is
the optimal role of invasive therapy for the treatment of
claudication? Many of the older members of the audience
were brought up on the notion that surgery and its associ-
ated risks should be taken very seriously and offered only
to individuals with persuasive indications. This and other
studies, however, may be interpreted as suggesting that this
basic tenet of vascular surgery be reexamined. If the most
important outcome of treatment is the “feel-good” score
or some modification thereof and we have available such
easy treatments as angioplasty, perhaps we should let down
the barriers and begin performing angioplasty on everyone,
as appears to be happening in certain centers in this coun-
try presently. When the angioplasty fails, as it always does,
we could simply perform angioplasty again. If a few limbs
are lost along the way and healthcare costs escalate, this
may be accepted as the price that one has to pay. This new
trend concerns me. I do suggest to the upcoming genera-
tions that surgical principles that have stood the test of time
should be dismissed with great caution. Invasive treatment
of small aneurysms, moderate intermittent claudication,
and 50% carotid stenosis will never appeal to me.
I appreciate the willingness of the Society to allow me
to ramble on. Thank you.
Dr Walter J. McCarthy, III. Thank you, Dr Porter. Dr
Porter’s somewhat irascible comments do not reveal the fact
that during the last few weeks he has reviewed our manu-
script and helped us substantially with some of the data
analysis. In fact, some of the conclusions that I was able to
make today come directly from his own imagination.
The term “feel-good” score might be fairly close to
the truth. For many conditions that we treat, the way the
patients feel probably is the bottom line, as in the cases for
claudication.
The validation of the SF36 actually has been tremen-
dously extensive. The last number of different diagnoses
that have been addressed by the SF36 that I know of is
153, ranging from hip replacement to vision dysfunction
to urinary tract problems. There have been literally thou-
sands of papers submitted with the SF36, so that you can
compare the reproducibility of scores between different
papers. We can say, for example, that the usual improve-
ment of the functional score after total hip replacement is
in the 20s and 30s, and in the present study involving
patients who have undergone correction of their arterial
stenosis with bypass grafting, our improvement was 28.
We are right up there with the level of the highest increase
ever reported in the physical functioning score.
Dr Porter’s comment about the small ankle brachial
index change that we all recognize as insignificant when a
single patient comes back to the blood flow laboratory and
has an increase or decrease of only 0.1 is completely dif-
ferent in a large group of patients in which a mean has
changed by the same amount. When you have a large
group of patients, this mean difference becomes a very
powerful statistical change.
Selection bias is what Dr Porter was concerned about in
a study like ours, which is nonrandomized. Selection bias
always rears its ugly head, and what we tried to do was to
pick out a matched medical group. We selected from our
medical group patients who had characteristics similar to the
interventionally managed patients. This control group had
minimal changes in their functional status over time. In the
Veteran’s Affairs system, it turns out that we are all conserv-
ative with the management of claudication, and many of the
Veteran’s Affairs patients probably would have been treated
with intervention if they had been seen in different settings.
Dr Porter. Any chance of a randomized study in there
somewhere?
Dr McCarthy. You know, we have thought about doing
a randomized study. I have written a proposal for such a
study in the Veteran’s Affairs system, but it has not been
submitted.
Dr Porter. Do you think we should lower the barriers for
the treatment of claudication? I am serious about that one.
Dr McCarthy. Well, the question is the risk. We have
shown that there is benefit. There are two questions really—
the cost and the risk. We do not know exactly what the risk
is. In our group, most of the patients were managed conser-
vatively. Only 20% of the patients were treated for their clau-
dication. In some clinics, as you said, who knows how many
patients, perhaps more than half or even more than two
thirds, are treated with intervention. In our group, in which
20% were treated, there were five lower limbs lost from 526
patients—more than one thousand limbs at risk over the 18-
month follow-up period. Two of those cases were patients
who had been in the medical group and were so debilitated
that when they had increasing limb ischemia they ended up
having a primary amputation. One patient underwent a
femoropopliteal bypass grafting procedure and then a year
later ended up with an amputation. Two other patients had
rest pain develop, underwent distal bypass grafting, and
eventually lost their limbs. So, all told, there was not much
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carnage related to the interventions in this group. Should we
lower the barriers of treatment? This paper does not solve
that problem. It simply shows that patients carefully, and I
believe conservatively, selected for treatment by a sophisti-
cated medical community do have benefit after treatment
and have little risk of limb loss as the result of intervention.
Dr Jack L. Cronenwett (Lebanon, NH). I enjoyed
your paper and applaud your application of this extra
dimension to the analysis of the outcome of these patients.
I have two questions.
First, if I interpreted your SF36 scores correctly, it
looked as if they were lower initially for the group of
patients who were treated surgically, implying that those
patients had more severe problems to begin with. My
question is, when you analyze the subsequent change in an
SF36 score, is it the absolute change that is important or
is it the relative change? In other words, if a patient
improves from a score of 20 to 40, is that a two-fold
improvement or is it the absolute difference that is rele-
vant? How linear is this scale as you interpret it?
My second question relates to what appeared to be a
high correlation between the change in ankle-brachial index
and your functional outcome scores as presented in your
subgroup analysis. As surgeons, we have been criticized for
only paying attention to these hemodynamic changes, but it
appears from your data that those actually might have a high
correlation with the functional outcome. Did you specifical-
ly look at the correlation between the change in ankle-
brachial index and the relative functional outcomes?
Dr McCarthy. Thank you. The importance of the rela-
tive change in the SF36 physical function score at different
parts of the scale is not known as far as we could determine.
What we assume is that if our group changes from a low
score and goes up 28 points, whereas patients with a total
hip replacement start at a much higher level and go up 28
points, that our group may have achieved a greater increase.
We have thought about it, and we really are not sure.
The r value for ankle-brachial index versus functional sta-
tus was analyzed in the enrollment data of this study, which
was published, and it does correlate. The r value is about
0.18, which is low. The r value for the patients who had
change after bypass grafting is quite a bit higher, about 0.6.
Dr John V. White (Philadelphia, Pa). I would like to
compliment you on an excellent study and a very interest-
ing collaborative effort.
You had a glimpse, during a short period of 18 months,
of patients who had undergone angioplasty, and you
looked at their improvement with several measures, such as
physical functioning score, the Walking Impairment
Questionnaire, and the ankle-brachial index. Did you get a
sense in that patient population of the converse: ie, if
restenosis was occurring at an angioplasty site, which scores
began to reflect that? Did the patients indicate a reduction
in distal flow in their physical functioning scores first? Did
the ankle-brachial index drop first, or did the Walking
Impairment Questionnaire change?
Dr McCarthy. That is an interesting question, but we
did not survey the patients in enough detail to answer it.
We were examining patients every 6 months. If we had
done it once a week, we probably would have had the
detail to comment.
Dr Kenneth Granke (Morgantown, WVa). Would you
give me your impression or your thoughts on the idea that
patients who are treated with claudication who now can
exercise better and actually feel better will perhaps do
more towards changing or modifying their behaviors that
are counterproductive for long-term results? That is, are
they more likely to quit smoking, change their diet, and
maintain a regular exercise program? Did you get any of
that information from this study?
Dr McCarthy. The question is whether patients who
are willing to exercise more are also willing to modify their
risk factors. That was not something that we were able to
analyze, but I presume that it is true.
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